Metabolism and disposition of [14C]dibromoacetonitrile in rats and mice following oral and intravenous administration
Tissue distribution, metabolism, and disposition of oral (0.2-20 mg/kg) and intravenous (0.2 mg/kg) doses of [2-14C]dibromoacetonitrile (DBAN) were investigated in male rats and mice. [14C]DBAN reacts rapidly with rat blood in vitro and binds covalently. Prior depletion of glutathione (GSH) markedly...
Saved in:
Published in | Xenobiotica Vol. 40; no. 7; pp. 499 - 509 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Informa UK Ltd
01.07.2010
Taylor & Francis |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Tissue distribution, metabolism, and disposition of oral (0.2-20 mg/kg) and intravenous (0.2 mg/kg) doses of [2-14C]dibromoacetonitrile (DBAN) were investigated in male rats and mice.
[14C]DBAN reacts rapidly with rat blood in vitro and binds covalently. Prior depletion of glutathione (GSH) markedly diminished loss of DBAN. Chemical reaction with GSH readily yielded glutathionylacetonitrile.
About 90% of the radioactivity from orally administered doses of [14C]DBAN was absorbed. After intravenous administration, 10% and 20% of the radioactivity was recovered in mouse and rat tissues, respectively, at 72 h. After oral dosing, three to four times less radioactivity was recovered, but radioactivity in stomach was mostly covalently bound.
Excretion of radioactivity into urine exceeded that in feces; 9-15% was exhaled as labeled carbon dioxide and 1-3% as volatiles in 72 h.
The major urinary metabolites were identified by liquid chromatography-mass spectrometry, and included acetonitrile mercaptoacetate (mouse), acetonitrile mercapturate, and cysteinylacetonitrile.
The primary mode of DBAN metabolism is via reaction with GSH, and covalent binding may be due to reaction with tissue sulphydryls. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0049-8254 1366-5928 |
DOI: | 10.3109/00498251003802298 |